Recently AUSTAR has signed a consulting service contract with a leading global healthcare company and a prominent player in the insulin market. Collaborating with the client, we will provide comprehensive consulting and process engineering services, complying with international quality standards, and implementation of sustainable development strategies. As the market continues to expand, drug profiles improve, indications broaden, and competition intensifies, GLP-1 therapies are expected to become the mainstream treatment for diabetes and obesity in the years ahead—and the top single-product sellers in their class.. - Product：Insulin & GLP-1 - Project standard：EMA, FDA, NMPA cGMP - Facility type：Greenfield - Project area：25000 ㎡ - Project-Driven：Rapidity, compliance